Back

PARADISE-MI Trial - Win Ratio Analysis.

29 August 2022 (09:42 - 09:52)
Organised by:
Congress Presentation Part of: HOT LINE SESSION 8 Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Otavio Berwanger

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

14 More presentations in this session

Presentation thumbnail
ISCHEMIA-CKD EXTEND - Clinical Outcomes at 5 years of Follow-up.
Professor S. Bangalore (New York, US)
Slides Video
Presentation thumbnail
Discussant review - ISCHEMIA-CKD EXTEND.
Professor D. Bhatt (New York City, US)
Slides Video
Presentation thumbnail
Panel discussion - ISCHEMIA-CKD EXTEND.
Video
Presentation thumbnail
15-month results of the MASTER DAPT trial.
Professor M. Valgimigli (Lugano, CH)
Slides Video
Presentation thumbnail
Discussant review - MASTER DAPT.
Professor S. Schuepke (Munich, DE)
Slides Video

Access the full session

Session thumbnail
HOT LINE SESSION 8
Video

The Event

Event poster

ESC Congress 2022

29 August 2022 09:42 CET
You may be interested in
thumbnail
Congress Presentation
Sacubitril/valsartan compared to ramipril in high risk post myocardial infarction patients stratified according use of mineralocorticoid receptor antagonists: Insight from PARADISE MI trial
29 August 2022
thumbnail
Congress Presentation
Analysis of DELIVER and DAPA-HF using win statistics
22 May 2023
thumbnail
Congress Session
Cardiology Toolbox - Clinical trial design
31 August 2025
thumbnail
Congress Presentation
Sacubitril/valsartan vs. valsartan initiation in patients with heart failure and EF>40% who are naive to renin-angiotensin-system inhibitors: Insights from PARAGLIDE-HF
12 May 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources